Analysis Indicates FHLC Could Reach $79
ETF Performance Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $79.22, indicating a potential upside of 13.87% from its current trading price of $69.57.
Notable Holdings with Upside: Key underlying holdings of FHLC, such as Mind Medicine Mindmed Inc (MNMD), Sana Biotechnology Inc (SANA), and Mirum Pharmaceuticals Inc (MIRM), show significant upside potential based on analyst target prices, with MNMD having an 85.91% upside.
Market Sentiment and Analyst Targets: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they are not aligned with current market conditions.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analyst targets in light of recent developments in the companies and the healthcare industry.
Trade with 70% Backtested Accuracy
Analyst Views on FHLC
No data
About the author
Experts Predict FHLC Will Hit $81
Fidelity MSCI Health Care Index ETF Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $81.28, indicating a potential upside of 15.88% from its current trading price of $70.14.
Notable Holdings with Upside Potential: Key underlying holdings of FHLC, such as Xeris Biopharma Holdings (XERS), Mineralys Therapeutics (MLYS), and iRadimed Corp (IRMD), show significant upside potential based on analyst target prices, with XERS at 38.16% higher, MLYS at 21.59%, and IRMD at 17.06%.
Analyst Target Price Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets relative to current prices could lead to potential downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent developments in the companies and the healthcare industry.
Analysis Indicates FHLC Could Reach $79
ETF Performance Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $79.22, indicating a potential upside of 13.87% from its current trading price of $69.57.
Notable Holdings with Upside: Key underlying holdings of FHLC, such as Mind Medicine Mindmed Inc (MNMD), Sana Biotechnology Inc (SANA), and Mirum Pharmaceuticals Inc (MIRM), show significant upside potential based on analyst target prices, with MNMD having an 85.91% upside.
Market Sentiment and Analyst Targets: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they are not aligned with current market conditions.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analyst targets in light of recent developments in the companies and the healthcare industry.
Analysts Predict FHLC Will Hit $78
ETF Performance Overview: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $78.46, indicating a potential upside of 12% from its current trading price of $70.06.
Notable Holdings with Upside: Key underlying holdings of FHLC, such as MoonLake Immunotherapeutics (MLTX), Prestige Consumer Healthcare Inc (PBH), and AtriCure Inc (ATRC), show significant upside potential based on analyst target prices, with MLTX expected to rise by 77.88%, PBH by 35.21%, and ATRC by 34.73%.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they do not align with recent developments in the companies or industry.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of the analysts' targets and to understand the implications of the current market conditions on these price predictions.
Calculating the Components: FHLC May Have a Value of $77
ETF Performance Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $77.05, indicating an 11.27% upside from its current trading price of $69.25.
Notable Holdings with Upside: Key underlying holdings such as Ocular Therapeutix Inc (OCUL), Phreesia Inc (PHR), and Collegium Pharmaceutical Inc (COLL) show significant potential for price increases, with target prices suggesting upside of 72.65%, 41.42%, and 34.30% respectively.
Putting It All Together: FHLC May Be Valued at $77
ETF Analyst Target Price: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $76.76 per unit, indicating an 11.75% upside from its recent trading price of $68.69.
Notable Holdings with Upside: Key underlying holdings of FHLC, such as Nutex Health Inc (NUTX), Twist Bioscience Corp (TWST), and Merit Medical Systems, Inc. (MMSI), show significant potential for price increases based on analyst targets, with NUTX having a target price 141.86% higher than its current price.
FHLC's Investments May Offer 16% Growth Opportunity
ETF Performance Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $76.02, indicating a potential upside of 15.68% from its current trading price of $65.72.
Notable Holdings with Upside: Key underlying holdings such as Liquidia Corp (LQDA), Avadel Pharmaceuticals PLC (AVDL), and Pulse Biosciences Inc (PLSE) show significant upside potential, with target prices suggesting increases of 60.26%, 26.25%, and 25.28% respectively from their recent trading prices.
Experts Predict FHLC Will Hit $81
Fidelity MSCI Health Care Index ETF Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $81.28, indicating a potential upside of 15.88% from its current trading price of $70.14.
Notable Holdings with Upside Potential: Key underlying holdings of FHLC, such as Xeris Biopharma Holdings (XERS), Mineralys Therapeutics (MLYS), and iRadimed Corp (IRMD), show significant upside potential based on analyst target prices, with XERS at 38.16% higher, MLYS at 21.59%, and IRMD at 17.06%.
Analyst Target Price Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets relative to current prices could lead to potential downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent developments in the companies and the healthcare industry.
Analysis Indicates FHLC Could Reach $79
ETF Performance Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $79.22, indicating a potential upside of 13.87% from its current trading price of $69.57.
Notable Holdings with Upside: Key underlying holdings of FHLC, such as Mind Medicine Mindmed Inc (MNMD), Sana Biotechnology Inc (SANA), and Mirum Pharmaceuticals Inc (MIRM), show significant upside potential based on analyst target prices, with MNMD having an 85.91% upside.
Market Sentiment and Analyst Targets: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they are not aligned with current market conditions.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analyst targets in light of recent developments in the companies and the healthcare industry.
Analysts Predict FHLC Will Hit $78
ETF Performance Overview: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $78.46, indicating a potential upside of 12% from its current trading price of $70.06.
Notable Holdings with Upside: Key underlying holdings of FHLC, such as MoonLake Immunotherapeutics (MLTX), Prestige Consumer Healthcare Inc (PBH), and AtriCure Inc (ATRC), show significant upside potential based on analyst target prices, with MLTX expected to rise by 77.88%, PBH by 35.21%, and ATRC by 34.73%.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they do not align with recent developments in the companies or industry.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of the analysts' targets and to understand the implications of the current market conditions on these price predictions.
Calculating the Components: FHLC May Have a Value of $77
ETF Performance Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $77.05, indicating an 11.27% upside from its current trading price of $69.25.
Notable Holdings with Upside: Key underlying holdings such as Ocular Therapeutix Inc (OCUL), Phreesia Inc (PHR), and Collegium Pharmaceutical Inc (COLL) show significant potential for price increases, with target prices suggesting upside of 72.65%, 41.42%, and 34.30% respectively.
Putting It All Together: FHLC May Be Valued at $77
ETF Analyst Target Price: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $76.76 per unit, indicating an 11.75% upside from its recent trading price of $68.69.
Notable Holdings with Upside: Key underlying holdings of FHLC, such as Nutex Health Inc (NUTX), Twist Bioscience Corp (TWST), and Merit Medical Systems, Inc. (MMSI), show significant potential for price increases based on analyst targets, with NUTX having a target price 141.86% higher than its current price.
FHLC's Investments May Offer 16% Growth Opportunity
ETF Performance Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $76.02, indicating a potential upside of 15.68% from its current trading price of $65.72.
Notable Holdings with Upside: Key underlying holdings such as Liquidia Corp (LQDA), Avadel Pharmaceuticals PLC (AVDL), and Pulse Biosciences Inc (PLSE) show significant upside potential, with target prices suggesting increases of 60.26%, 26.25%, and 25.28% respectively from their recent trading prices.
